Reynders McVeigh Capital Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,274 shares of the biopharmaceutical company’s stock after selling 1,860 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in Pfizer were worth $1,723,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Vanguard Group Inc. raised its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Pfizer by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after acquiring an additional 1,085,437 shares in the last quarter. Institutional investors and hedge funds own 70.06% of the company’s stock.

Pfizer Inc. (NYSE:PFE) opened at $34.66 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $206,600.00, a PE ratio of 9.85, a P/E/G ratio of 1.93 and a beta of 0.94. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.47 EPS. research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is 38.64%.

Pfizer declared that its Board of Directors has approved a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Several research firms have weighed in on PFE. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. UBS Group set a $42.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, January 31st. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $39.45.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

WARNING: “Reynders McVeigh Capital Management LLC Has $1.72 Million Holdings in Pfizer Inc. (PFE)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/reynders-mcveigh-capital-management-llc-has-1-72-million-holdings-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.